These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35204197)

  • 1. Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma.
    Sathyasaikumar KV; Pérez de la Cruz V; Pineda B; Vázquez Cervantes GI; Ramírez Ortega D; Donley DW; Severson PL; West BL; Giorgini F; Fox JH; Schwarcz R
    Antioxidants (Basel); 2022 Feb; 11(2):. PubMed ID: 35204197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
    Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
    J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
    Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington's disease.
    Bondulich MK; Fan Y; Song Y; Giorgini F; Bates GP
    Sci Rep; 2021 Mar; 11(1):5484. PubMed ID: 33750843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kynurenine pathway metabolic balance influences microglia activity: Targeting kynurenine monooxygenase to dampen neuroinflammation.
    Garrison AM; Parrott JM; Tuñon A; Delgado J; Redus L; O'Connor JC
    Psychoneuroendocrinology; 2018 Aug; 94():1-10. PubMed ID: 29734055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
    Oxenkrug G; van der Hart M; Roeser J; Summergrad P
    Integr Clin Med; 2017; 1(1):. PubMed ID: 28748226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drosophila eye color mutants as therapeutic tools for Huntington disease.
    Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
    Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
    Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
    Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition.
    Phillips RS; Iradukunda EC; Hughes T; Bowen JP
    Front Mol Biosci; 2019; 6():3. PubMed ID: 30800661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
    Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
    Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
    Tashiro T; Murakami Y; Mouri A; Imamura Y; Nabeshima T; Yamamoto Y; Saito K
    Behav Brain Res; 2017 Jan; 317():279-285. PubMed ID: 27693848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
    Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
    J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
    Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
    Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.